Daily chart presents some strength with recent news release relating to Opgen expanding testing in the state of New York with the use of their “Acuitas AMR gene panel”
The product is (RUO) research use only, as is has not yet been approved by the FDA. I believe that with the current market, it’s highly likely that the gap should be filled within this week, and will likely see a move to higher price ranges wIth more and more investors expecting a favorable decision from the FDA
News was as expected, I think we will see something in the near term!